Loading market dashboard
GeneDx Holdings Corp.
WGSHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
New York, New York--(Newsfile Corp. - June 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit PR Newswire NEW YORK, June
NEW YORK, June 6, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 6, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
New York, New York--(Newsfile Corp. - June 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 3, 2026.
NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna and Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut on behalf of all persons or entities who purchased or otherwise acquired GeneDx Holdings Corp.
NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut on behalf of all persons or entities who purchased or otherwise acquired GeneDx Holdings Corp. (“WGS” or the “Company”) (NASDAQ: WGS) securities between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”).
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WG
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026. GeneDx describes itself as an “American biotechnology company specializing in genomic diagnostics, with a focus on whole genome sequencing and whole exome sequencing for the diagnosis of rare and inherited disorders.”For more information, submit a form, email attorney P.
LOS ANGELES--(BUSINESS WIRE)---- $WGS--WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm.
New York, New York--(Newsfile Corp. - June 5, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
ATLANTA, June 05, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against GeneDx Holdings Corp. (“GeneDx ”) (NASDAQ: WGS). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding GeneDx's acquisition of Fabric Genomics and its impact on GeneDx's business, operations, and prospects.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 5, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition - Hagens Berman
SAN FRANCISCO, June 5, 2026 /PRNewswire/ -- GeneDx Holdings (NASDAQ: WGS) faces a securities class action after the price of the company's stock cratered $33.42 (-49%) on May 5, 2026 in response to the company's disastrous Q1 2026 earnings report. The lawsuit seeks to represent investors who purchased shares of GeneDx common stock between April 16, 2025 and May 4, 2026.
SAN DIEGO, June 4, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), have until August 3, 2026 to seek appointment as lead plaintiff of the GeneDx class action lawsuit. Captioned Basma v.
SAN DIEGO--(BUSINESS WIRE)---- $WGS #Biogenetics--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026. GeneDx Holdings Corp is a genomics company that provides genetic testing services for diagnosing pediatric and rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbin.
GeneDx Holdings (WGS) 49% Drop Triggers Investor Scrutiny Over Disconnect From Prior Growth Narrative- HBSS PR Newswire
[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. (âGeneDxâ or the
SAN FRANCISCO, June 4, 2026 /PRNewswire/ -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) saw the price of their shares tank $33.42 (-49%) on May 5, 2025 after the company announced a massive Q1 2026 earnings miss, a tenfold increase in net loss, and a drastic reduction in full-year 2026 guidance. The stock's move lower wiped out over $900 million from GeneDx's market capitalization in a single day.
NEW YORK--(BUSINESS WIRE)---- $WGS #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm h.
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GeneDx securities between April 16, 2025 and May 4, 2026, both dates inclusive (the "Class Period").
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GeneDx securities between April 16, 2025 and May 4, 2026, both dates inclusive (the “Class Period”).
During the first quarter of 2026, the largest portfolio sector weightings were Health Care and Industrials. RBC Bearings Incorporated, Cognex Corporation and Nebius Group were among the top contributors to performance. Repligen Corporation, Agilysys, Inc., and GeneDx Holdings Corp. were among the top detractors from performance.
PHILADELPHIA, June 04, 2026 (GLOBE NEWSWIRE) -- Barrack, Rodos & Bacine (“BRB”) announces that it has filed a class action lawsuit in the United States District Court for the District of Connecticut, captioned Basma v. GeneDx Holdings Corp., et al., Case No. 3:26-cv-00880, on behalf of persons and entities that purchased or otherwise acquired GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) securities between April 16, 2025, and May 4, 2026, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
SAN FRANCISCO, May 28, 2026 /PRNewswire/ -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) saw the price of their shares tank $33.42 (-49%) on May 5, 2025 after the company announced a massive Q1 2026 earnings miss, a tenfold increase in net loss, and a drastic reduction in full-year 2026 guidance. The stock's move lower wiped out over $900 million from GeneDx's market capitalization in a single day.
SAN FRANCISCO, May 27, 2026 (GLOBE NEWSWIRE) -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) saw the price of their shares tank $33. 42 (-49%) on May 5, 2025 after the company announced a massive Q1 2026 earnings miss, a tenfold increase in net loss, and a drastic reduction in full-year 2026 guidance.
SAN FRANCISCO, May 27, 2026 (GLOBE NEWSWIRE) -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) saw the price of their shares tank $33.42 (-49%) on May 5, 2025 after the company announced a massive Q1 2026 earnings miss, a tenfold increase in net loss, and a drastic reduction in full-year 2026 guidance. The stock's move lower wiped out over $900 million from GeneDx's market capitalization in a single day.
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that management will participate in the Goldman Sachs Healthcare Conference from June 8-10 in Miami, FL.
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
AI-driven health intelligence provider GeneDx attracted a notable insider buy, as recent filings highlight activity amid a volatile year.
PHILADELPHIA, May 20, 2026 (GLOBE NEWSWIRE) -- The law firm of Barrack, Rodos & Bacine announces that it is investigating GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of shareholders who have lost money in their investment in GeneDx stock.
GeneDx posted Q1 2026 revenue of $102.3 million against consensus estimates near $110 million and reported adjusted EPS of -$0.28 versus the -$0.01 expected -- the stock collapsed approximately 44% in a single session. NEW YORK, May 20, 2026 /PRNewswire/ -- Shareholders who held GeneDx Holdings Corp. (NASDAQ: WGS) stock lost approximately 44% of their investment value when the company reported Q1 2026 results that fell sharply below Wall Street expectations.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In GeneDx (WGS) To Contact Him Directly To Discuss Their Options
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.
New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GeneDx Holdings Corp. (NASDAQ: WGS) ("GeneDx Holdings Corp.") concerning potential violations of the federal securities laws. On its Q4 2025 earnings call on February 23, 2026, CFO Kevin Feeley told investors the company expected "adjusted net income positive for the full year and each individual quarter" of 2026.
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
GeneDx stock collapsed approximately 44% after Q1 2026 earnings revealed a major revenue miss and a roughly 12% cut to full-year guidance -- weeks after management publicly reaffirmed its outlook GeneDx stock collapsed approximately 44% after Q1 2026 earnings revealed a major revenue miss and a roughly 12% cut to full-year guidance -- weeks after management publicly reaffirmed its outlook
GeneDx Holdings Corp. specializes in advanced exome and genome diagnostic testing, leveraging its proprietary GeneDx Infinity dataset for superior interpretation. Q1 2026 results missed expectations, and guidance for the year was reduced primarily as a result of shifting product mix dynamics and delayed sales cycles. Blended test pricing was adversely impacted by the lower-priced, lower-margin genomic testing segment, which grew faster than anticipated.
NEW YORK, May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.
GeneDx CFO promised quarterly profitability weeks before the company posted an $8.2 million adjusted loss -- and then cut full-year guidance by approximately 12%. NEW YORK, May 13, 2026 /PRNewswire/ -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) lost approximately 44% of their share value after Q1 2026 earnings revealed a significant revenue miss and a roughly 12% cut to full-year guidance.
GeneDX (WGS) experienced a 50% stock drop after Q1 misses and FY26 guidance cut, yet volume grew 34% YoY, outpacing internal forecasts. Revenue shortfall was due to mix shift toward lower-ARR genome tests and non-core weakness, not demand or pricing issues. Genome adoption is accelerating, supporting a bullish thesis as payer coverage expands, automation improves, and new channels like general pediatrics ramp.
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
PHILADELPHIA, May 12, 2026 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) The law firm of Barrack, Rodos & Bacine announces that it is investigating GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of shareholders who have lost money in their investment in GeneDx stock.
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.
Boston, Massachusetts--(Newsfile Corp. - May 11, 2026) - Block & Leviton is investigating GeneDX Holdings Corp. (NASDAQ: WGS) for potential securities law violations. Investors who have lost money in their GeneDX Holdings Corp. investment should contact the firm to learn more about how they might recover those losses.
New York, New York--(Newsfile Corp. - May 11, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GeneDx Holdings Corp. ("GeneDx Holdings Corp.") (NASDAQ: WGS) concerning potential violations of the federal securities laws. On its Q4 2025 earnings call on February 23, 2026, CFO Kevin Feeley told investors the company expected "adjusted net income positive for the full year and each individual quarter" of 2026.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In GeneDx (WGS) To Contact Him Directly To Discuss Their Options
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
New York, New York--(Newsfile Corp. - May 7, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GeneDx Holdings Corp. ("GeneDx Holdings Corp.") (NASDAQ: WGS) concerning potential violations of the federal securities laws. On its Q4 2025 earnings call on February 23, 2026, CFO Kevin Feeley told investors the company expected "adjusted net income positive for the full year and each individual quarter" of 2026.
PHILADELPHIA, May 07, 2026 (GLOBE NEWSWIRE) -- The law firm of Barrack, Rodos & Bacine announces that it is investigating GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of shareholders who have lost money in their investment in GeneDx stock.
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On May 4, 2026, GeneDx released its first quarter 2026 financial results, revealing earnings per sha.
Boston, Massachusetts--(Newsfile Corp. - May 6, 2026) - Block & Leviton is investigating GeneDX Holdings Corp. (NASDAQ: WGS) for potential securities law violations. Investors who have lost money in their GeneDX Holdings Corp. investment should contact the firm to learn more about how they might recover those losses.
ATLANTA, May 06, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) complied with federal securities laws. On May 4, 2026, GeneDx reported its first quarter 2026 results and revised its guidance. Total revenue was $12 million lower than expected, which the Company attributed to: “mix dynamics resulting in a lower-than-expected blended average reimbursement rate and softer noncore business line performance.” The price of the Company's stock dropped following this news.
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON GENEDX HOLDINGS CORP. (WGS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happened?On M.
One of these stocks plummeted 49% on Tuesday.
